| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one manufacturers
- IMS2186
-
- $41.00
-
2026-07-27
- CAS:1031206-36-6
- Purity: 99.96%
- Supply Ability: 10g
|
| | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one Basic information |
| Product Name: | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one | | Synonyms: | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one;IMS2186;4H-1-Benzopyran-4-one, 2,3-dihydro-3-[(3-hydroxy-4-methoxyphenyl)methylene]-6-methyl-, (3E)-;(E)-3-(3-Hydroxy-4-methoxybenzylidene)-6-methylchroman-4-one;(3E)-2,3-Dihydro-3-[(3-Hydroxy-4-Methoxyphenyl)Methylene]-6-Methyl-4H-1-Benzopyran-4-One;IMS2186, 10 mM in DMSO;UDP-GlcNAz disodium | | CAS: | 1031206-36-6 | | MF: | C18H16O4 | | MW: | 296.32 | | EINECS: | | | Product Categories: | | | Mol File: | 1031206-36-6.mol | ![3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one Structure](CAS/20180703/GIF/1031206-36-6.gif) |
| | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one Chemical Properties |
| Boiling point | 535.7±50.0 °C(Predicted) | | density | 1.286±0.06 g/cm3(Predicted) | | storage temp. | room temp | | solubility | DMSO: >20mg/mL | | pka | 9.39±0.10(Predicted) | | form | solid | | color | white to off-white | | InChI | 1S/C18H16O4/c1-11-3-5-16-14(7-11)18(20)13(10-22-16)8-12-4-6-17(21-2)15(19)9-12/h3-9,19H,10H2,1-2H3/b13-8+ | | InChIKey | BZCADTHMZLYKAR-MDWZMJQESA-N | | SMILES | COc1ccc(cc1O)\C=C2/COc3ccc(C)cc3C2=O |
| Hazard Codes | N | | Risk Statements | 50/53 | | Safety Statements | 60-61 | | RIDADR | UN 3077 9 / PGIII | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Aquatic Acute 1 Aquatic Chronic 1 |
| | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one Usage And Synthesis |
| Uses | IMS2186 is an anti-prileferative and anti-angiogenic compound. | | Biological Activity | IMS2186 is an anti-proliferative and anti-angiogenic agent. Apparently IMS2186 blocks the cell cycle at G2 and inhibits the production of PGE2/TNF-α. IMS2186 inhibits cell growth in vitro in tumor cells, non-transformed fibroblasts, and retinal pigment epithelial cells. IMS2186 inhibits angiogenesis (IC50 = 0.1 μM) and cell migration. Intraocular injection of IMS2186 could be a long-lasting effective treatment for CNV (choroidal neovascularization) in AMD (age-related macular degeneration) with a reduction in scarring and related visual loss. | | in vivo | IMS2186 (2.5 mg in 0.5 mL; intravitreal injection; single dose) has no ocular toxicity while applied to rabbit eyes[1].
IMS2186 (100 μg/eye, i.e. 2.0 μL of the solution of 50 μg/μL; single dose) shows anti-proliferative effect on laser-induced choroidal neovascularization (CNV) rat models[1].
| Animal Model: | Rat model of laser induced CNV[1] | | Dosage: | 100 μg/eye, 2.0 μL of the solution of 50 μg/μL | | Administration: | Intravitreal injection; single dose | | Result: | Resulted 30% reduction of lesion area compared to PBS in the lesion area measurement. |
|
| | 3-[1-(3-Hydroxy-4-methoxyphenyl)-meth-(E)-ylidene]-6-methyl-chroman-4-one Preparation Products And Raw materials |
|